All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.

The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy


Now you can personalise
your ALL Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more

The ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
You're logged in! Click here any time to manage your account or log out.
You're logged in! Click here any time to manage your account or log out.

ASH 2023 abstracts: What’s hot in ALL?

Dec 4, 2023

Bookmark this article

To help navigate the exciting content being presented at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition, the ALL Hub Steering Committee members have provided their recommendations for the top abstracts to look out for in ALL.

Frontline and emerging therapies for ALL


RPT1G: A 1st-in-class small molecule NAMPT inhibitor as a novel therapeutic for acute lymphocytic leukemia


Risk-adjusted therapies yield equivalent outcomes for adolescents and young adults (AYAs) treated for newly diagnosed t-cell acute lymphoblastic leukemia (t-all) on Children’s Oncology Group (COG) studies AALL0434 and AALL123


Outcome of infants treated on total therapy for infants with acute lymphoblastic leukemia I: results from a non-randomized multi-center study


Patients with down syndrome and high-risk B-acute lymphoblastic leukemia demonstrate improved outcomes on a modified chemotherapy regimen: a report from Children’s Oncology Group study AALL1131


Pediatric patients with high-risk b-cell all in first complete remission may benefit from less toxic immunotherapy with blinatumomab – results from randomized controlled phase 3 trial AIEOP-BFM all 2017


Sequential chemotherapy and blinatumomab to improve minimal residual disease in adult ph- b-lineage acute lymphoblastic leukemia. Final results of the phase II gimema LAL2317 trial


Olverembatinib combined with venetoclax and reduced-intensity chemotherapy for patients with newly diagnosed philadelphia chromosome-positive acute lymphoblastic leukemia: early results from a phase II study


CNS irradiation in adult de novo B-precursor ALL / LBL: results of the randomized GMALL trial 08/2013 indicate potential antileukemic efficacy


Dasatinib and CAR-T cell therapy for newly diagnosed ph-positive acute lymphoblastic leukemia in adults


Feasibility and outcome of post-induction therapy incorporating dasatinib for patients with newly diagnosed ABL-class fusion B-lymphoblastic leukemia (ABL-class fusion B-all): Children’s Oncology Group AALL1131


Frontline consolidation with nelarabine for adults with high-risk t-cell acute lymphoblastic leukemia. Results of the GRAAII-2014/T Atriall phase 2 study


Nelarabine (nel), pegylated asparginase (peg) and venetoclax (ven) incorporated to HCVAD chemotherapy in the frontline treatment of adult patients with T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/T-LBL)


Dose reduced chemotherapy in sequence with blinatumomab for newly diagnosed older patients with Ph/BCR::ABL negative B-precursor adult lymphoblastic leukemia (ALL): preliminary results of the GMALL bold trial


Efficacy and safety of recombinant erwinia asparaginase (JZP458) in acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL): complete follow-up of the Children’s Oncology Group (COG) AALL1931 study


Long-term follow up for SWOG 1318: combination of dasatinib, prednisone, and blinatumomab for older patients with Philadelphia-chromosome (Ph) positive acute lymphoblastic leukemia (ALL)


Impact of high-risk cytogenetics (HR-CTG) on the outcome of newly diagnosed adult patients with Philadelphia negative B-cell acute lymphoblastic leukemia (B-ALL) treated with frontline blinatumomab (blina) and/or inotuzumab ozogamicin (ino) containing hypercvad (HCVAD) therapy


Frontline combination of 3rd generation TKI olverembatinib and blinatumomab for Ph+/Ph-like all patients


Chemotherapy-sparing induction followed by consolidation and maintenance with blinatumomab and concurrent oral tyrosine kinase inhibitor therapy for newly-diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: primary endpoint results from the Blissphall study


A phase i/ii study to investigate the addition of venetoclax to dasatinib and steroids in patients with newly diagnosed or relapsed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL): the Venda Trial, in progress


Chemotherapy-free combination of blinatumomab and ponatinib in adults with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia: updates from a phase II trial


A phase ii study of low-intensity chemotherapy (mini-hyper-cvd) and ponatinib followed by blinatumomab and ponatinib in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia


Venetoclax combined with hag regimen in newly diagnosed ETP-ALL: interim analysis of a prospective, multicenter, phase 2 trial


A phase 1 study of venetoclax in combination with a pediatric-inspired regimen for the treatment of newly diagnosed adults with B-cell Ph-like ALL


Ponatinib versus imatinib in patients with newly diagnosed Ph+ all: subgroup analysis of the phase 3 Phallcon study


Combination of olverembatinib and vp regimen as first-line therapy for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia


Updated results on a multicenter phase II study of a dose intensified pediatric regimen in adults with acute lymphoblastic leukemia: the 06-254 DFCI ALL consortium trial


Reduced-dose chemotherapy followed by blinatumomab as induction therapy in treatment of newly diagnosed Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia - interim results from a multicenter, single-arm, phase 2 study


Updated results from a phase II study of hyper-cvad, with or without inotuzumab ozogamicin, and sequential blinatumomab in patients with newly diagnosed B-cell acute lymphoblastic leukemia


Comparison between dasatinib-blinatumomab vs ponatinib-blinatumomab chemo-free strategy for newly diagnosed Ph+ acute lymphoblastic leukemia patients. Preliminary results of the Gimema ALLL2820 trial


Long-term results of the frontline dasatinib/blinatumomab protocol (d-alba, Gimema LAL2116) for adult Ph+ acute lymphoblastic leukemia

Treatment for relapsed/refractory ALL


Phase 1/2 dose-escalation/dose-expansion study of anti-cd7 allogeneic CAR-T cells (WU-CART-007) in relapsed or refractory (r/r) t-cell acute lymphoblastic leukemia/ lymphoblastic lymphoma (T-ALL/LBL)


Efficacy and safety of interleukin-6-knockdown CD19-targeted CAR T cells(ssCART-19) for relapsed/refractory B-ALL


Blinatumomab in combination with immune checkpoint inhibitors (icis) of PD-1 and CTLA-4 in adult patients with relapsed/refractory (r/r) CD19 positive B-cell acute lymphoblastic leukemia (ALL): results of a phase I study


Venetoclax combined with azacitidine was effective and safe for relapsed/refractory T-cell acute lymphoblastic leukemia/ lymphoblastic lymphoma: preliminary results of a phase 2, multicenter trial


Venetoclax and blinatumomab for adult patients with relapsed/refractory or mrd positive Ph-negative B-precursor all: first results of the GMALL-Bliven trial


A phase I study of venetoclax in combination with inotuzumab ozogamicin for relapsed or refractory all in adults


Results from the phase 1 portion of a trial of oral ixazomib combined with chemotherapy in relapsed/refractory acute lymphoblastic leukemia or lymphoma in children, adolescents and young adults: a report from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium


First-in-human study of the CD123 NK cell engager SAR443579 in relapsed or refractory acute myeloid leukemia, b-cell acute lymphoblastic leukemia or high risk-myelodysplasia: updated safety, efficacy, pharmacokinetics and pharmacodynamics


A multicenter study of CAR-T cell therapy for relapse of B-ALL post allogeneic stem cell transplantation


Efficacy and safety of the second CAR-T therapy in patients with refractory/relapsed acute B-cell lymphoblastic leukemia


A phase 1 study of CD38-bispecific antibody (XmAB18968) for patients with relapsed/refractory T-cell acute lymphoblastic leukemia


Updated results of the phase I BALLI-01 trial of ucart22 process 2 (P2), an anti-CD22 allogeneic CAR-T cell product manufactured by cellectis biologics, in patients with relapsed or refractory (r/r) cd22+ b-cell acute lymphoblastic leukemia (B-ALL)


Revumenib monotherapy in patients with relapsed/refractory KMT2Ar acute leukemia: topline efficacy and safety results from the pivotal augment-101 phase 2 study

Allogeneic transplantation


Comparable outcome after busulfan- or treosulfan-based conditioning regimen in children above 4 years of age with all undergoing allogeneic hsct. Results from the Prospective International Forum-Trial


Addition of inotuzumab ozogamicin to the conditioning regimen of allogeneic stem cell transplantation (allo-SCT) for relapsed CD22 (+) lymphoid malignancies: long-term survival results


Short-term blinatumomab as a bridge therapy for hematopoietic stem cell transplantation in B-cell acute lymphoblastic leukemia with low leukemia burden


Cd7 chimeric antigen receptor T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation remarkably improved long-term disease-free survival in refractory/relapsed T-cell acute lymphoblastic leukemia/lymphoma


Role of allogeneic stem cell transplantation in preventing relapse in adult BCR::ABL1-like acute lymphoblastic leukemia


Incidence and risk factors for central nervous system relapse after allogeneic hematopoietic stem cell transplantation in adult patients with acute lymphoblastic leukemia


How much have post-transplant outcomes improved since 2000 for patients with Philadelphia-positive acute lymphoblastic leukemia in first remission? A study from the EBMT Acute Leukemia Working Party


Allogeneic hematopoietic stem cell transplantation for elderly acute lymphoblastic leukemia patients: a registry study from the société francophone de greffe de moelle et thérapie cellulaire (SFGM-TC)


Prognostic factors impacting post-transplant outcomes in adult t-cell acute lymphoblastic leukemia: a registry-based study by the EBMT Acute Leukemia Working Party


Clinical outcomes of adults undergoing allogeneic stem cell transplant for secondary acute lymphoblastic leukemia


Outcomes and prognostic factors of second allogeneic hematopoietic cell transplantation in patients with acute lymphoblastic leukemia: a study from the Adult Acute Lymphoblastic Leukemia Working Group of the Japanese Society for Transplantation and Cellular Therapy

Real-world evidence

Socioeconomic challenges

Molecular biomarkers


Risk factors for CD19-targeting CAR T manufacturing failure and patient outcomes: a report from the UK National CAR T Panel


Association between high antimetabolite dose intensity during maintenance, toxicities and relapse risk in children with acute lymphoblastic leukemia (ALL): COG-AALL03N1 report


Single cell transcriptomic analysis of B-cell acute lymphoblastic leukemia (B-all) reveals correlation between leukemia cell state, genetic alterations and clinical outcome


NGS-based stratification refines the risk stratification in T-ALL and identifies a very high-risk subgroup of patients


Achievement of undetectable BCR::ABL1 (UBCR::ABL1) is predictive of improved survival in Philadelphia chromosome positive (Ph+ve) acute lymphoblastic leukemia (ALL) patients not receiving allogeneic stem cell transplantation


Low disease burden pre-CAR T-cell therapy for children and AYA with B-ALL is associated with an impaired outcome when obtained through intensification of the bridging therapy


Inflammatory signatures define a new high-risk T-lineage ALL subtype


Genomic determinants of therapy response in ETV6::RUNX1 leukemia


Drug response profiling of childhood T-cell acute lymphoblastic leukemia to inform functional precision medicine


The CNS microenvironment promotes leukemia cell survival by disrupting tumour suppression and cell cycle regulation in pediatric T-cell acute lymphoblastic leukemia


Exploring the heterogeneity of response to blinatumomab in high-risk philadelphia-negative B-cell precursor acute lymphoblastic leukemia: an analysis from the quest sub-study of the Graall-2014/B trial


Drug response profiling informs personalized bridging to cell therapy for patients with relapsed/refractory acute lymphoblastic leukemia

Treatment-related toxicities


ASH 2023 abstracts

To download this document, click below.

Download here

More about...


Subscribe to get the best content related to ALL delivered to your inbox